Clinical-stage allosterically acting drugs are on track to unlock a stubborn class of targets.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. Phosphatases start shedding their stigma of undruggability. Nat Rev Drug Discov 17, 847–849 (2018). https://doi.org/10.1038/nrd.2018.201
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.201
- Springer Nature Limited
This article is cited by
-
Emerging roles of the Protein Phosphatase 1 (PP1) in the context of viral infections
Cell Communication and Signaling (2024)
-
The protein phosphatase-2A subunit PR130 is involved in the formation of cytotoxic protein aggregates in pancreatic ductal adenocarcinoma cells
Cell Communication and Signaling (2024)
-
Inhibition of PPP1R15A alleviates osteoporosis via suppressing RANKL-induced osteoclastogenesis
Acta Pharmacologica Sinica (2024)
-
SHP2 clinical phenotype, cancer, or RASopathies, can be predicted by mutant conformational propensities
Cellular and Molecular Life Sciences (2024)
-
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas
Nature Cancer (2024)